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Abstract: The antimicrobial activity of different essential oils (EOs) from the Lamiaceae family was
evaluated on Streptococcus agalactiae, Candida albicans, and lactobacilli. S. agalactiae is the main cause
of severe neonatal infections, such as sepsis, meningitis, and pneumonia. C. albicans is a primary
causative agent of vulvovaginal candidiasis, a multifactorial infectious disease of the lower female
reproductive tract. Lactobacilli represent the dominant bacterial species of the vaginal flora and
constitute the natural defense against pathogens. On the basis of the preliminary results, the attention
was focused on the EOs from Lavandula x intermedia Emeric ex Loisel. and Mentha arvensis L. By using
gas ghromatography (GS) retention data and mass spectra, it was possible to identify more than
90% of the total composition of the EO samples. The minimal inhibitory concentration (MIC) and
anti-biofilm activity of the two EOs were determined against all isolated strains, using the EOs
by themselves or in combination with each other and with drugs (erythromycin and fluconazole).
The results showed a good antimicrobial and anti-biofilm activity of both EOs and a synergistic
effect, leading to the best results against all the strains, resulted using the combinations EOs/EOs and
antimicrobials/EOs.
Keywords: essential oil; Lamiaceae; Lavandula x intermedia; Mentha arvensis; Streptococcus agalactiae;
Candida albicans; antibiotics; synergic associations; anti-biofilm activity
1. Introduction
The vaginal flora is strongly related to women health. The vaginal ecosystem is typically dominated
by different Lactobacillus species, mainly Lactobacillus crispatus, Lactobacillus gasseri, Lactobacillus iners,
and Lactobacillus jensenii. They play a protective role by a combination of various mechanisms,
i.e., by maintaining a low pH (<4.5), by a specific adhesion to the vaginal tissue, and by the production
of inhibitory substances (e.g., organic acids, hydrogen peroxide, bacteriocins), thus reducing the
development of most pathogenic microorganisms [1,2]. The lactobacilli reduction leads to an alteration
of vaginal flora and, consequently, favors the pathogenic bacterial growth with health outcomes.
Streptococcus agalactiae, also known as the Group B Streptococcus (GBS), is a Gram-positive, facultative
anaerobe and an opportunistic pathogen for pregnant women, newborns, and elderly persons. GBS
colonizes the female genital tract (50% of the female population), the gastrointestinal tract and the
urethra of both men and women [3]. Between 10 and 30% of pregnant women are intermittently or
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persistently colonized by GBS and they are at risk of transmitting this pathogen to their newborn infant
in the perinatal period [4,5]. GBS can be life-threatening, when it is vertically transmitted through
the birth canal from a colonized mother to her newborn at birth, causing pneumonia, meningitis,
and sepsis.
The most accepted medical procedure for the detection of GBS in pregnant women is a maternal
screening for clinical risk factors at delivery or rectovaginal colonization only at 35–37 weeks of
gestation and, in the presence of this pathogen, a subsequent intrapartum antibiotic prophylaxis is
prescribed [6]. With few exceptions, GBS remains fully susceptible to penicillin. However, about 10%
of pregnant women are allergic to penicillin and an alternative to this antibiotic should be administered.
Erythromycin and clindamycin are the most used treatments, but GBS has increased over time its
resistance to these drugs [7].
Candida albicans is a normal constituent of human flora, and a common colonizer of mucosal
membrane, skin, gastrointestinal tract, and vaginal mucosa. In more than 75% of cases, this species
behaves as an opportunistic pathogen responsible for vulvovaginal candidiasis (VVC) [8–11]. The ability
of Candida species to form biofilm is considered as a critical point in its pathogenesis, with an increased
resistance to traditional antimycotic agents [9,12–14]. Fluconazole is the first-line antifungal agent
used in clinical VVC infections [13]. However, variable sensitivity or resistance to this drug reduces
the effectiveness of the treatment, thus inducing recurrent vaginal candidiasis [10,15–21].
This growing trend indicates that there is a crucial need for highly efficient antibacterial and
antifungal alternative agents with few side effects. The vast structural diversity of natural compounds
of plant origin provides a unique opportunity for discovering new bioactive molecules. In this ambit,
essential oils (EOs) represent an alternative to conventional antimicrobial treatments, due to their
broad-spectrum activity against microorganisms, mainly as a consequence of the alteration of the
microbial membrane and cell wall, with resulting loss of cytoplasmic material. EOs biological activities
are due to their complex chemical composition and presence of phenols, which are compounds of
interest for the treatment of both bacterial and fungal infections [9,22–27].
In this work, different essential oils (EOs) belonging to the Lamiaceae family were evaluated for
their antimicrobial activity against two S. agalactiae and two C. albicans strains isolated from vaginal
swabs. Four Lactobacillus strains were also tested since, during women fertile age, they represent 90%
of vaginal flora, and they play an important role in protecting the host from genital infections.
2. Results
2.1. Agar Disk Diffusion Assay
As shown in Table S1, erythromycin and fluconazole displayed their activity against Streptococcus
agalactiae and Candida albicans strains, respectively. These two antimicrobials used as the reference
showed their activity also towards lactobacilli. By using the agar disk diffusion method and considering
the zone of inhibition, it was also possible to verify the EOs inhibitory activity against all the
microorganisms tested. Among the EOs used, Lavandula x intermedia Emeric and Mentha arvensis L.
were the most active against all C. albicans strains, even if a less evident activity of M. arvensis EO
towards the C. albicans 2 strain emerged. L. x intermedia showed also a good antibacterial activity against
S. agalactiae, in particular, towards S. agalactiae ATCC 13813. Satureja montana and Thymus vulgaris EOs
displayed good activity against S. agalactiae, while their activity towards C. albicans strains was lower
than L. x intermedia and M. arvensis EOs. M. arvensis EO exhibited also antimicrobial activity against
lactobacilli, if compared to L. x intermedia EO. L. x intermedia EO was selected for further chemical
analysis, due to its excellent antimicrobial activity against S. agalactiae and C. albicans strains and its low
activity towards lactobacilli. M. arvensis was chosen for its activity against candida, a microorganism
found to be frequently resistant to fluconazole, the first-line antifungal agents used in clinical VVC
infections, and often responsible for recurrent vaginal diseases.
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2.2. Qualitative and Semi-Quantitative Analysis of EOs
On the basis of the preliminary results obtained by the agar disk diffusion assay, a phytochemical
characterization of L. x intermedia and M. arvensis EOs was carried out by means of gas chromatography
(GC). By using retention data, mass spectra, and data reported in the literature, it was possible to
identify the analytes in all the EO samples (Table 1). More than 90% of the total composition for each
EO was characterized.
Table 1. Qualitative and semi-quantitative analysis of Lavandula x intermedia and Mentha arvensis
essential oils (EOs). Data are expressed as % relative peak area values ± standard deviation (SD).
Compound a LRI b Lavandula x intermedia Mentha arvensis
α-Thujene 926 0.1 c -
α-Pinene 931 0.7 c 0.7 c
Camphene 946 0.5 c -
Sabinene 971 0.2 c 0.3 c
β-Pinene 974 0.5 c 0.8 c
β-Myrcene 990 1.0 ± 0.1 0.7 c
p-Cymene 1024 0.3 c -
Limonene 1027 1.4 c 3.6 ± 0.1
1,8-Cineole 1029 5.0 c 0.2 c
cis-Ocimene 1037 0.8 c -
trans-Ocimene 1047 0.9 c -
γ- Terpinene 1058 0.1 c -
Terpinolene 1087 0.4 c -
Linalool 1100 36.0 ± 0.1 0.1 c
Camphor 1143 5.9 ± 0.1 -
Isopulegol 1146 - 0.8 c
Menthone 1156 - 7.8 ± 0.1
Borneol 1165 4.0 c -
Isomenthone 1167 - 5.4 c
Terpinen-4-ol 1177 2.7 c -
Menthol 1180 - 73.8 ± 0.2
α- Terpineol 1191 0.9 c 0.1 c
Pulegone 1245 - 0.5 c
Piperitone 1259 - 0.5 c
Linalyl acetate 1263 27.3 ± 0.2 -
Lavandulyl acetate 1293 1.8 c -
Menthyl Acetate 1297 - 2.1 c
β-Bourbonene 1390 - 0.1 c
β-Caryophyllene 1424 1.5 c 0.3 c
Germacrene D 1487 - 0.4 c
Caryophyllene oxide 1592 0.2 c -
Total 92.1 98.2
a Compounds are listed in order of elution. b Linear retention index (LRI) calculated on a HP-5 column. c SD < 0.05.
L. x intermedia EO showed a composition rich in linalool (36.0%), linalyl acetate (27.3%). Other
peculiar constituents of this hybrid were camphor (5.9%), 1,8-cineole (5.0%), and borneol (4.0%) [28,29].
M. arvensis EO main compounds included menthol (73.8%), menthone (7.8%), isomenthone (5.4%),
limonene (3.6%), and menthyl acetate (2.1%). The two EOs composition was in accordance with the
data reported in the literature [30].
2.3. Minimum Inhibitory Concentration (MIC)
The minimum inhibitory concentrations (MICs) against all strains of both antimicrobials confirmed
the results of the disk diffusion test (Table 2). As regards the EOs, the best antimicrobial activity was
observed for L. x intermedia EO, with values ranging from 9 to 18 µg/mL against all S. agalactiae and
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C. albicans strains. M. arvensis EO, as already observed with the agar disk diffusion assay, resulted less
active against all the pathogenic strains, with values ranging from 18 to 144 µg/mL. On the contrary,
higher MIC values were obtained for all the Lactobacillus strains treated with L. x intermedia EO than
with M. arvensis EO.
Table 2. Minimum inhibitory concentration (MIC) of EOs in comparison with the two reference
antimicrobials (erythromycin and fluconazole). Data are expressed as µg/mL.
Strains Lavandula x intermedia Mentha arvensis Erythromycin Fluconazole
Streptococcus agalactiae 1 18 36 2 -
Streptococcus agalactiae 2 9 18 1 -
Streptococcus agalactiae ATCC 13813 18 18 0.125 -
Candida albicans 1 18 18 - 4
Candida albicans 2 9 144 - 4
Candida albicans ATCC 10231 18 72 - 0.25
Lactobacillus spp.1 144 9 0.5 1
Lactobacillus spp.2 144 18 0.25 1
Lactobacillus spp.3 72 18 0.25 1
Lactobacillus spp.4 72 18 1 0.5
2.4. Determination of the Fractional Inhibitory Concentration Index (FICI)
The fractional inhibitory concentration (FIC) index evaluation indicated the absence of antagonistic
effects and showed several synergistic interactions, in particular, between the two EOs against
S. agalactiae and C. albicans strains (Table S2). Furthermore, it is important to underline the synergistic
effect of the two EOs with erythromycin and fluconazole, even if less evident for the combination
M. arvensis EO/erythromycin. The synergic combination as this could allow a decrease in the
concentration of antimicrobial necessary for the therapeutic treatment.
2.5. Time–Kill Studies
The results of time–kill studies are shown in Figures 1 and 2. Both EOs were active against
all S. agalactiae and C. albicans strains, even if L. x intermedia EO was more effective than M. arvensis
EO. A synergistic activity against S. agalactiae and C. albicans was observed with the combination
antimicrobial/EO, and in particular when the two antimicrobials were used in association with
L. x intermedia EO. The synergistic activity also emerged with the combination EO/EO against all
S. agalactiae and C. albicans test strains. Lastly, M. arvensis EO reduced the presence of lactobacilli
more than L. x intermedia EO. The anti-lactobacilli activity was detected with the synergic combination
antibiotic/EO and EO/EO only for two Lactobacillus strains. Erythromycin and fluconazole activity
against all tested strains confirmed the sensitivity patterns.
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Figure 1. Time–kill studies of L. x intermedia, . arvensis EOs, antimicrobials (erythromycin and
fluconazole) and of different combinations (antimicrobial/EO and EO/EO) against Streptococcus agalactiae
and Candida albicans strains. p-values of <0.05, p < 0.01, p < 0.001 and p < 0.0001 were considered
significant by t-test and ANOVA.
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Figure 2. Time–kill studies of L. x intermedia, . arvensis EOs, antimicrobials (erythromycin and
fluconazole), and of different combinations (antimicrobial/EO and EO/EO) against Lactobacillus spp.
strains. p-values of <0.05, p < 0.01, p < 0.001 and p < 0.0001 were considered significant by t-test
and ANOVA.
2.6. Anti-Biofilm Activity Determination
Erythromycin and all the combinations (EO/EO and antibiotic/EO) were effective against the
mature biofilm of S. agalactiae strains. The synergistic effect of the EOs used in combination resulted
more evident against the ’48 h old’ mature biofilm and, for the single EO, with a significant difference
with the control (range of p-value from 0.004112 to 0.001285). Concerning C. albicans strains, C. albicans
Antibiotics 2020, 9, 592 6 of 16
2 and C. albicans ATCC 10231 in particular, fluconazole and the synergistic combinations (EO/EO and
antifungal/EO) showed an excellent anti-biofilm activity. In the whole, L. x intermedia EO exhibited a
better activity than M. arvensis EO against both the ‘24 h and 48 h old’ mature biofilm, proving to be
the most effective product capable of counteracting its development (Figure 3).
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Lastly, L. x intermedia EO did not exhibit a remarkable activity towards the ‘24 h and 48 h old’
mature biofilm produced by Lactobacillus strains. Conversely, M. arvensis EO, fluconazole, and all the
associations showed a good anti-biofilm activity against ‘24 h old’ mature biofilm of the same (p-value
ranging from 0.0324 to 0.0041) (Figure 4).
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Figure 4. Anti-biofilm activity of L. x intermedia, M. arvensis EOs, antimicrobials (erythromycin and
fluconazole), and of different combinations (antimicrobial/EO and EO/EO) against Lactobacillus spp.
strains. Results were expressed in OD 570 nm as the arithmetic mean of the three determinations.
p-values of <0.05 (*), p < 0.01 (**), p < 0.001 (***) and p < 0.0001 (****) were considered significant by
t-test and ANOVA.
2.7. Quantification of EOs Activity on Mature Biofilm by Fluorescence Assay Study
We investigated biofilm changes following single EOs and their combination treatments.
The ‘24 h old’ mature biofilm was treated either with the EOs alone or in combination (EO/EO
and antimicrobial/EO) and then stained with CFDA and PI to define a numerical quantification of live
and dead cells.
The EOs from L. x intermedia and M. arvensis, as well as the combinations (EO/EO and
antimicrobial/EO) strongly reduced the number of viable cells of all tested strains (Figures 5 and 6).
L. x intermedia EO was more active against S. agalactiae and C. albicans strains in comparison with
M. arvensis EO. On the other hand, L. x intermedia EO was less effective against all tested lactobacilli,
as previously observed.
2.8. Effectiveness of EOs Activity on Mature Biofilm by Fluorescence Microscopy Study
The anti-biofilm activity was assessed against all tested strains, by using live/dead staining in
association with the observation under a fluorescence microscope. After treatment with the EOs
themselves and their combinations (EO/EO and antimicrobial/EO), an abundant red fluorescence
indicating dead cells in the polymeric matrix of S. agalactiae, C. albicans, and lactobacilli biofilm was
observed (Figure 7). With regard to these last strains, the presence of viable lactobacilli in the sample
treated with L. x intermedia EO once again indicates the reduced impact of this EO on the natural
protective vaginal microflora.
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and Lactobacillus spp. (3c) mature biofilm treated with M. arvensis EO; S. agalactiae (1d), C. albicans
(2d) and Lactobacillus spp. (3d) mature biofilm treated with synergistic combination EO/EO. Green
fluorescence labels live cells, whereas red fluorescence labels dead cells. The scale bars indicate 10 µm.
3. Discussion
EOs are widely used as a possible alternative therapy for their antimicrobial effects [31,32].
The screening of medical plants, and in particular of those rich in EOs, for antibacterial and antifungal
activities is important to find new active antimicrobial compounds. Many studies on the antibacterial
activity of Lavandula EOs have been based on Lavandula angustifolia Miller [29,33], even if other varieties,
such L. x intermedia, have shown therapeutic potential [34]. Lavandula species have also demonstrated to
be a weapon against antimicrobial resistant pathogens responsible for human infections [35–38]. Many
studies have focused on the antibacterial effects of Lavandula volatile compounds, such as linalool,
linalyl acetate, and terpinen-4-ol [39,40]. EOs from Mentha species have also been used as a folk
medicine, due to their antibacterial and antifungal activities attributed to high levels of monoterpenes,
including menthol and menthone [41–43]. M. arvensis, also known as wild mint or corn mint, is one
species with a high content of menthol (80–95%) [44].
In this study, two EOs (i.e., L. x intermedia and M. arvensis) were selected from a panel of EOs
belonging to the Lamiaceae family on the basis of their antimicrobial activity against S. agalactiae and
C. albicans, vaginal colonizers, and opportunistic pathogens, respectively. S. agalactiae colonizes female
genital tract and it is the main cause of neonatal diseases, being transmitted vertically from a colonized
mother to her newborn at birth [3–5]. Candida vaginitis is a complicated disease with wide-reaching
effects that are governed by fungal biology and host physiology and response [9].
The natural defense against infections in the vaginal tract includes microbial flora, such as
lactobacilli, which are believed to interfere with pathogens [19]. Several clinical studies have highlighted
an inverse correlation between the presence of Lactobacillus species and S. agalactiae in female vaginal
tract [45,46]. Lactobacilli can be able to protect from Candida colonization and infection because of their
capability to adhere and compete for vaginal mucosa adhesion sites [47].
In light of all the above, the chemical characterization as well as the antibacterial and antifungal
activities of L. x intermedia and M. arvensis EOs against S. agalactiae, C. albicans, and Lactobacillus species
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were assessed. The results clearly indicated that these EOs, having a high content of linalool and
linalyl acetate for L. x intermedia and menthol for M. arvensis, respectively, showed a good antimicrobial
activity against the two vaginal pathogens, in planktonic and in biofilm forms, both individually and
in association with each other and with drugs (erythromycin and fluconazole). As reported for other
medical and aromatic plants belonging to the Lamiaceae family, the anti-biofilm activity of EOs may
occur through the modulation of certain genes involved in adhesion, a feature essential for biofilm
formation and pathogenesis of microorganisms [48].
Other authors have already described the antimicrobial activity of Lavandula and Mentha
EOs against Candida albicans and S. agalactiae isolated from vaginal swabs [49]. In addition,
Minooeianhaghighi et al. have demonstrated that Lavandula EO is able to inhibit C. albicans, also in
association with other EOs. The antibacterial activity of Lavandula EO seems closely related to amount
of 1,8-cineol [49]. The anti-candida activity of Mentha EO has been described by other authors [50].
Pietrella et al. have found an antifungal activity of Mentha EO against azole-resistant C. albicans
strains [50]. The antibacterial activity of these EOs could be due to their ability to degrade membrane
proteins and cell permeability. Regarding anti-biofilm formation, EOs are able to inhibit adhesion of
bacterial cells at the first stage of biofilm formation, which might be due to their capability to inhibit the
quorum sensing (QS) activity, that enables bacterial cells to have a multicellular behavior [51]. Further
study of the anti-QS activity of EOs should be analyzed in detail.
The single EOs and their combinations exhibited antibacterial activity also towards lactobacilli. L. x
intermedia EO was the less active against lactobacilli, thus allowing the recognized protective function
of lactic flora on vaginal mucosa. Therefore, this natural product could be used in the clinical field for
the control of the pathogens, respecting the survival of lactobacilli. Nevertheless, further studies are
needed, especially on the activity and toxicity of the EO constituents, that can be also responsible for
undesirable effects, such as irritation, blushes, phototoxicity, sensitizations, which are still limiting
their medicinal use.
4. Materials and Methods
4.1. Chemicals and Reagents
All reference standards used for GC analysis, chromatographic grade organic solvents, and reagents
were purchased from Sigma-Aldrich (Milan, Italy).
4.2. Essential Oils
Authentic EOs samples from L. x intermedia, M. arvensis, Origanum vulgare L., Satureja montana L.,
and Thymus vulgaris L., all obtained by hydrodistillation, were kindly provided by Alchimia Natura
srl (Modena, Italy). The samples were stored at low temperature (+4 ◦C), protected from light and
humidity, until required for chemical analysis.
4.3. Microbial Strains
All the strains were collected in June 2017 from the Provincial Laboratory of Clinical Microbiology
‘S. Agostino-Estense’ Hospital (Modena, Italy). Vaginal swabs of women aged between 25 to 40
were randomly selected. The C. albicans (n = 2, C. albicans IP01 and C. albicans IP02) and S. agalactiae
(GBS) (n = 2, S. agalactiae IP03 and S. agalactiae IP04) strains were isolated on CHROMID agar
(CHROMID® Candida® Candida, bioMérieux, Milan, Italy) and on group B Streptococcus differential
agar (CHROMID® Strepto B, bioMérieux, Milan, Italy), respectively. Four strains of lactobacilli
(Lactobacillus spp. 1-IP04, Lactobacillus spp. 2-IP05, Lactobacillus spp. 3-IP06, and Lactobacillus spp.
4-IP07) were also isolated in Man-Rogosa Sharpe agar (MRS agar, bioMérieux, Milan, Italy).
All the isolates were confirmed by matrix-assisted laser desorption ionization (MALDI)
time-of-flight mass spectrometry (TOF/MS). C. albicans ATCC 10231 and S. agalactiae ATCC 13813 were
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included as positive controls. All strains were maintained in the same media containing 20% (w/v)
glycerol at −80 ◦C until use.
4.4. Agar Disk Diffusion Assay
The preliminary determination of the effectiveness of the above mentioned EOs against all the
microorganisms was carried out by using the agar disk diffusion assay, according to the standard
procedure of the Clinical and Laboratory Standards Institute [52]. Sterile disks of 6 mm in diameter,
containing 10 µL of each EO, were placed on Tryptic Soy Agar (TSA, Oxoid) plates, previously seeded
with 100 µL of 106 CFU/mL of cell suspensions. Erythromycin (15 µg) and fluconazole (25 µg) discs
were used as the positive controls. After incubation at 37 ◦C for 24 h, in anaerobic condition for
GSB and lactobacilli strains, the antagonistic activity of the EOs was quantified by a clear zone of
inhibition in the indicator lawn around the disks and the diameters in millimeters of these zones were
measured [53].
4.5. GC Analysis
GC-MS analyses were performed on a 7890A gas chromatograph coupled with a 5975C network
mass spectrometer (Agilent Technologies, Germany). Compounds were separated on an Agilent
Technologies HP-5 MS cross-linked poly-5% diphenyl–95% dimethyl polysiloxane (30 m × 0.25 mm
i.d., 0.25 µm film thickness) capillary column. The column temperature was initially set at 45 ◦C,
then increased at a rate of 2 ◦C/min up to 100 ◦C, then raised to 250 ◦C at a rate of 5 ◦C/min and finally
held for 5 min. The injection volume was 0.1 µL, with a split ratio 1:20. Helium was used as the carrier
gas, at a flow rate of 0.7 mL/min. The injector, transfer line, and ion-source temperature were 250, 280,
and 230 ◦C, respectively. MS detection was performed with electron ionization (EI) at 70 eV, operating
in the full-scan acquisition mode in the m/z range 40–400. EOs were diluted 1:20 (v/v) with n-hexane
before GC-MS analysis.
GC analyses with flame ionization detector (FID) were carried out on a 7820 A from Technologies.
Compounds were separated on an Agilent Technologies HP-5 cross-linked poly-5% diphenyl–95%
dimethyl polysiloxane (30 m × 0.32 mm i.d., 0.25 µm film thickness) capillary column. The temperature
program was the same as described above. The injection volume was 0.1 µL in the split mode 1:20.
Helium was used as the carrier gas at a flow rate of 1.0 mL/min. The injector and detector temperature
were set at 250 and 300 ◦C, respectively. The EOs and the reference standards were diluted to 1:20 (v/v)
with n-hexane before GC-FID analysis. The analyses were performed in triplicate for each sample.
4.6. Qualitative and Semi-Quantitative Analysis
Compounds were identified by comparing the retention times of the chromatographic peaks with
those of authentic reference standards run under the same conditions and by comparing the LRIs
relative to C8-C40 n-alkanes obtained on the HP-5 column under the above-mentioned conditions with
the literature [54]. Peak enrichment by co-injection with authentic reference compounds was also
carried out. Comparison of the MS-fragmentation pattern of the target analytes with those of pure
components was performed. A mass-spectrum database search was carried out by using the National
Institute of Standards and Technology (NIST, Gaithersburg, MD, USA) mass-spectral database (version
2.0d, 2005).
Semi-quantification was calculated as the relative percentage amount of each analyte; in particular,
the values were expressed as the percentage peak area relative to the total composition of each EO
obtained by GC-FID analysis.
4.7. Minimum Inhibitory Concentration (MIC)
The MIC values of L. x intermedia and M. arvensis EOs were determined against all microorganisms
by means of a microwell dilution method. The test was performed in sterile 96-well microplates by
dispensing into each well 95 µL of nutrient broth and 5 µL of cell suspensions, to final inoculums
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concentrations of 106 CFU/mL. Then, 100 µL of EO serial dilutions were added to obtain concentrations
ranging from 512 to 0.25 µg/mL [55]. The last well, containing 195 µL of nutrient broth and 5 µL
of the test strains without EOs, was used as the negative control. The antibiotics erythromycin and
fluconazole, diluted in nutrient broth with strains added, were used as the positive control. The plates
were incubated at 37 ◦C for 24 h, mixed on a plate shaker at 300 rpm for 20 s, and the MIC was defined
as the lowest concentration of the EOs that inhibited visible growth of the tested microorganisms after
measuring the optical density (OD) at 570 nm, using a microtiter plate reader. All the experiments
were repeated three times.
4.8. Determination of the Fractional Inhibitory Concentration Index (FICI)
The checkerboard method was carried out in nutrient broth by using the microdilution method to
obtain the FICI for the combined application of L. x intermedia and M. arvensis EOs and the combined
effects of EOs and antimicrobials against all test strains. FICI was calculated as follows: MIC of the
combination of the EOs/MIC of the EO alone. EOs were combined at MIC + MIC, MIC + 1/2 MIC, MIC
+ 1/4 MIC, MIC + 1/8 MIC, 1/2 MIC + 1/2 MIC, 1/2 MIC + 1/4 MIC, 1/2 MIC + 1/8 MIC, 1/4 MIC + 1/4
MIC, 1/4 MIC + 1/8 MIC, and 1/8 MIC + 1/8 MIC. The results were considered as synergy (FIC ≤ 0.5),
addition (0.5 ≤ FIC ≥ 1), indifference (1 ≤ FIC ≥ 4), and antagonism (FIC > 4) [22].
4.9. Time–Kill Studies
The growth of all the test strains in contact with the corresponding antimicrobial, with L. x
intermedia and M. arvensis EOs and with the different combinations of EO/EO and antimicrobial/EO was
evaluated by calculating the change in the optical density of cells grown. In a 96-well sterile microplate,
90 µL of sterile nutrient broth and 10 µL of the strains were placed in each well from a stock, previously
diluted to obtain a density of about 105 CFU/mL. Antimicrobials and EOs were added at different
concentrations for each well, depending on the results obtained during the evaluation of the MIC
and of the fractional inhibitory concentration index. The microplate was incubated at 37 ◦C with an
oscillating speed of 150 rpm, and the optical density (OD) was determined at 595 nm at predetermined
time intervals (0, 6, 12 and 24 h) of exposure, using an automatic micro plate reader (Tecan Sunrise™).
The experiments were replicated three times.
4.10. Anti-Biofilm Activity Determination
The effect of both EOs, by themselves or in combination (EO/EO and antimicrobial/EO) was tested
on ’24 and 48 h old’ pre-formed biofilm, obtained using 96-well polystyrene microtiter plates, added
with approximately 105 CFU/mL of single microbial strains and incubated at 37 ◦C. After biofilm
formation, the medium was gently aspirated and plates were washed three times with a sterile
phosphate-buffered saline solution (PBS, pH 7.2) to remove planktonic bacteria, and the compounds
were added at MIC concentration. Following an additional incubation for 24 h at 37 ◦C, the biofilm
biomass was quantified according to the crystal violet staining method by Stepanovic et al. [56].
Absorbance values were measured at 570 nm using a microtiter plate reader.
4.11. Quantification of EOs Activity on Mature Biofilm by Fluorescence Assay Study
Wells containing mature ‘24 h old’ biofilm performed as above were washed with PBS solution,
and the EOs, by themselves or in combination (EO/EO and antimicrobial/EO), were added at MIC
concentration. After 24 h incubation treated and untreated wells (control) were washed twice with
sterile PBS and stained by the “live/dead cells stain kit” (Thermo Fisher Scientific, Waltham, MA, USA),
according to manufacturer instructions. The method is based on the use of propidium iodide (PI) as
marker of dead cells and 5(6)-carboxyfluorescein diacetate (cFDA) to detect alive cells. After incubation
in the dark at 37 ◦C for 30 min, the samples were washed twice with PBS and, to numerically quantify
the amount of live and died cells, the fluorescence emission (CFDA excitation/emission: 485/528;
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PI excitation/emission: 528/645) was analyzed using a multi-well fluorescence plate reader (Synergy
HTX, BIOTEK, Winooski, VT, USA). The results were expressed as relative fluorescence units (RFU).
4.12. Effectiveness of EOs Activity on Mature Biofilm by Fluorescence Microscopy Study
The effect of EOs on mature biofilm formation was evaluated in a 96-well microtiter plate,
as described above. Subsequently, each well was washed two times with PBS to remove the
unbound cells. Biofilm was fixed for 30 min with PBS-buffered 4% paraformaldehyde, then the
samples were washed twice with PBS, treated with Prolong Gold antifade (PLGAR) (Thermo Fisher
Scientific, Walthan, MA, USA) and stained by the “live/dead cells stain kit” (Thermo Fisher Scientific,
Waltham, MA, USA), according to manufacturer instructions. The method is based on the use of
propidium iodide (PI) as marker of dead cells and 5(6)-carboxyfluorescein diacetate (cFDA) to detect
alive cells. After incubation in the dark at room temperature for 30 min, biofilm was visualized by
epifluorescence microscopy Nikon Eclipse 90i imaging system, equipped with Normaski DIC optics
(Nikon Instruments Inc., Melville, NY, USA). Samples were photographed with a DS-2Mv Nikon
digital camera.
4.13. Statistical Analysis
Each experiment was replicated three times. The statistical significance was determined by t-test,
Qui-square test, and ANOVA test. The p-values were considered to be significant at ≤0.05.
5. Conclusions
In this study, L. x intermedia and M. arvensis EOs were selected from an initial panel of samples
belonging to the Lamiaceae family on the basis of their preliminary activity against S. agalactiae, C. albicans,
and lactobacilli, and their chemical composition was evaluated. The antimicrobial activity of the two
EOs by themselves and in combination against all strains both in planktonic and in biofilm form was
assessed. In particular, the association EO/EO and antimicrobial/EO gave interesting results. All of
these findings represent an advantage in an attempt to overcome drug resistance emergency in a period
like this, where even the most recent synthetic antimicrobial drugs are not enough effective against
multidrug-resistant bacteria.
In conclusion, these two EOs possess potential health benefit, especially that from L. x intermedia,
and they could be valuable in the pharmaceutical fields, such as in gynecology and obstetrics, for the
treatment of various symptoms and pathological conditions, and also for preventive purposes in
detergents for personal hygiene, ointments, creams and ovules.
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Table S1: Agar Well Disk diffusion assay of EOs and common antimicrobial drugs. The inhibition diameters were
measured in mm, Table S2: Minimal inhibitory concentration (MIC) and synergistic effect (FIC-INDEX) between
EOs and antimicrobials (erythromycin and fluconazole). Data are expressed as µg/mL.
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